As announced on December 11, 2025, we entered into a definitive agreement (the “Merger Agreement”) with Cycle, a United Kingdom-based company focused on rare genetic conditions in metabolic, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results